Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Alnylam Pharmaceuticals, Inc. Snapshot | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Alnylam Pharmaceuticals, Inc. Pipeline Review | 10 | 4 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Pipeline Products Partnered Products | 12 | 1 |
| Partnered Products/Combination Treatment Modalities | 13 | 1 |
| Alnylam Pharmaceuticals, Inc. Pipeline Products Glance | 14 | 5 |
| Alnylam Pharmaceuticals, Inc. Late Stage Pipeline Products | 14 | 1 |
| Phase III Products/Combination Treatment Modalities | 14 | 1 |
| Alnylam Pharmaceuticals, Inc. Clinical Stage Pipeline Products | 15 | 1 |
| Phase II Products/Combination Treatment Modalities | 15 | 1 |
| Phase I Products/Combination Treatment Modalities | 16 | 1 |
| Alnylam Pharmaceuticals, Inc. Early Stage Pipeline Products | 17 | 1 |
| Preclinical Products/Combination Treatment Modalities | 17 | 1 |
| Discovery Products/Combination Treatment Modalities | 18 | 1 |
| Alnylam Pharmaceuticals, Inc. Drug Profiles | 19 | 30 |
| patisiran | 19 | 1 |
| Product Description | 19 | 1 |
| Mechanism of Action | 19 | 1 |
| R&D Progress | 19 | 1 |
| revusiran | 20 | 1 |
| Product Description | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| R&D Progress | 20 | 3 |
| ALN-PCSsc | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 2 |
| fitusiran | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| ALN-AAT | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| ALN-CC5 | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 2 |
| ALN-GO1 | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 2 |
| ALN-HBV | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 2 |
| ALN-AS1 | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| ALN-TTRsc02 | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| ALN-VSP | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 2 |
| ALN-AC3 | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| ALN-AGT | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| ALN-ANG | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| ALN-PDL | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| ALN-TMP | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| Cellular Immunotherapy for Oncology and Viral Infections | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| ALN-HDV | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 1 |
| RNAi Oligonucleotide for Undisclosed Indication | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 1 |
| RNAi Oligonucleotides for Genetic Diseases | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 1 |
| RNAi Oligonucleotides for Hepatic Infections | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 1 |
| RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| R&D Progress | 48 | 1 |
| Alnylam Pharmaceuticals, Inc. Pipeline Analysis | 49 | 6 |
| Alnylam Pharmaceuticals, Inc. Pipeline Products by Target | 49 | 2 |
| Alnylam Pharmaceuticals, Inc. Pipeline Products by Route of Administration | 51 | 1 |
| Alnylam Pharmaceuticals, Inc. Pipeline Products by Molecule Type | 52 | 1 |
| Alnylam Pharmaceuticals, Inc. Pipeline Products by Mechanism of Action | 53 | 2 |
| Alnylam Pharmaceuticals, Inc. Recent Pipeline Updates | 55 | 28 |
| Alnylam Pharmaceuticals, Inc. Dormant Projects | 83 | 1 |
| Alnylam Pharmaceuticals, Inc. Company Statement | 84 | 2 |
| Alnylam Pharmaceuticals, Inc. Locations And Subsidiaries | 86 | 1 |
| Head Office | 86 | 1 |
| Other Locations &Subsidiaries | 86 | 1 |
| Appendix | 87 | 2 |
| Methodology | 87 | 1 |
| Coverage | 87 | 1 |
| Secondary Research | 87 | 1 |
| Primary Research | 87 | 1 |
| Expert Panel Validation | 87 | 1 |
| Contact Us | 87 | 1 |
| Disclaimer | 88 | 1 |